Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2:keab815. doi: 10.1093/rheumatology/keab815

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Fig. 1 — Antibody response to SARS-CoV-2 vaccination according to B cell depletion

(A) Schematic diagram representing the median time between the last RTX infusion, the first and second doses of vaccine, and the sampling for seropositivity testing the day of the new RTX infusion. (B) Distribution of SARS-CoV-2 spike antibody levels in the whole cohort. (C) S1/S2 antibody levels according to RTX-induced B cell depletion. Results are expressed as medians and 95% CI. ****P < 0.0001 by Mann–Whitney test. Dotted red line corresponds to the seropositivity threshold. (D) Cumulative seropositive rate (with 95% CI in red) according to CD19 counts. COVID-19: coronavirus disease 2019; RTX: rituximab; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.